Literature DB >> 14578160

Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma.

Kianoush Khaleghpour1, Yang Li, Denis Banville, Zhenbao Yu, Shi-Hsiang Shen.   

Abstract

The phosphoinositide 3-kinase (PI 3-kinase) signaling pathway has been shown to play a pivotal role in intracellular signal transduction pathways involved in cell growth, cellular transformation and tumorigenesis. Analysis of several colon adenocarcinoma cell lines indicates that the PI 3-kinase signaling pathway is up-regulated in colon cancers. In particular, the protein levels and phosphorylation status of Akt and p70 S6 kinase are up-regulated in colon adenocarcinoma cell lines. More significantly, we have demonstrated for the first time that the phosphorylation of FKHR, a downstream target of Akt, is increased in these cell lines. Intriguingly, phosphorylation of three components of the PI 3-kinase signaling pathway, namely Akt, p70 S6 kinase and FKHR, are in direct correlation with the degree of tumorigenic potential of the colon cell lines tested. No differences in the protein levels of the two subunits of PI 3-kinase, p85 and p110alpha, and PTEN were noted. Real-time quantitative PCR indicated an increase in levels of Akt message only, and not of the other signaling pathway components. Inhibition of the PI 3-kinase with wortmannin decreased the anchorage-independent growth of colon cells in a soft agar assay. Hence, the components of the PI 3-kinase signaling pathway could serve as potential candidates for drug development in treatment of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578160     DOI: 10.1093/carcin/bgg195

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  32 in total

1.  The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution.

Authors:  Huili Lu; Hongyu Liu; Jiaxian Wang; Jiaqing Shen; Shunyan Weng; Lei Han; Tao Sun; Lan Qian; Mingyuan Wu; Shunying Zhu; Yan Yu; Wei Han; Jianwei Zhu; Anja Moldenhauer
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-15       Impact factor: 4.553

2.  Increased cell survival, migration, invasion, and Akt expression in PTHrP-overexpressing LoVo colon cancer cell lines.

Authors:  Xiaoli Shen; Ramanjaneya V R Mula; B Mark Evers; Miriam Falzon
Journal:  Regul Pept       Date:  2007-01-10

3.  No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer.

Authors:  Lynette S Phillips; Cheryl L Thompson; Alona Merkulova; Sarah J Plummer; Thomas C Tucker; Graham Casey; Li Li
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

4.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

5.  FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells.

Authors:  Silvia Fernández de Mattos; Priam Villalonga; Jon Clardy; Eric W-F Lam
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

6.  The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population.

Authors:  Fangyuan Jing; Yingying Mao; Zhenyu Zhang; Yingjun Li; Shaofang Cai; Qilong Li; Xinyuan Ma; Mingjuan Jin; Kun Chen
Journal:  Tumour Biol       Date:  2014-06-17

Review 7.  Targeting stem cells-clinical implications for cancer therapy.

Authors:  Lan Chun Tu; Greg Foltz; Edward Lin; Leroy Hood; Qiang Tian
Journal:  Curr Stem Cell Res Ther       Date:  2009-05       Impact factor: 3.828

8.  Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells.

Authors:  Lobke Snoeks; Christopher R Weber; Jerrold R Turner; Mitra Bhattacharyya; Kaarin Wasland; Suzana D Savkovic
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

9.  Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models.

Authors:  R Minelli; S Occhipinti; C L Gigliotti; G Barrera; P Gasco; L Conti; A Chiocchetti; G P Zara; R Fantozzi; M Giovarelli; U Dianzani; C Dianzani
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

10.  Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.

Authors:  Pat Gulhati; Qingsong Cai; Jing Li; Jianyu Liu; Piotr G Rychahou; Suimin Qiu; Eun Y Lee; Scott R Silva; Kanika A Bowen; Tianyan Gao; B Mark Evers
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.